Rise Advisors’s Fulgent Genetics FLGT Stock Holding History

Rise Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18	Closed	-$407	–	590
2025 Q3	$407	Hold	18	–	–	﹤0.01%	1445
2025 Q2	$358	Hold	18	–	–	﹤0.01%	1460
2025 Q1	$304	Hold	18	–	–	﹤0.01%	1423
2024 Q4	$332	Sell	18 -29	-62%	-$566	﹤0.01%	1107
2024 Q3	$1.02K	Sell	47 -112	-70%	-$2.5K	﹤0.01%	1164
2024 Q2	$3.12K	Sell	159 -27	-15%	-$564	﹤0.01%	1098
2024 Q1	$4.04K	Hold	186	–	–	﹤0.01%	1101
2023 Q4	$5.38K	Sell	186 -172	-48%	-$4.6K	﹤0.01%	373
2023 Q3	$9.57K	Sell	358 -45	-11%	-$1.54K	0.01%	319
2023 Q2	$14.9K	Hold	403	–	–	0.01%	281
2023 Q1	$12.6K	Hold	403	–	–	0.01%	326
2022 Q4	$12K	Hold	403	–	–	0.01%	324
2022 Q3	$15K	Sell	403 -52	-11%	-$2.61K	0.01%	282
2022 Q2	$25K	Hold	455	–	–	0.03%	209
2022 Q1	$28K	Hold	455	–	–	0.03%	210
2021 Q4	$45.8K	Buy	+455	New	+$40K	0.04%	156

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rise Advisors's FLGT Position: Q4 2025 in Review

Rise Advisors sold out of Fulgent Genetics (FLGT) in Q4 2025, closing a stake of 18 shares — an estimated $407 sold.

Rise Advisors first reported a position in FLGT in Q4 2021 and held it in 16 quarters. The position peaked at $45.8K in Q4 2021. 179 funds tracked by Wall St. Rank hold FLGT as of Q4 2025.

Rise Advisors reported no remaining Fulgent Genetics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 18 Fulgent Genetics shares in Q4 2025, an estimated $407.
Rise Advisors first reported a position in Fulgent Genetics in Q4 2021 and held it in 16 quarters.
Rise Advisors's Fulgent Genetics position peaked at $45.8K in Q4 2021.
179 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.